Leading International Scientific Body Supports Call for Legalisation and Regulation to Reduce Cannabis-Related Harms

– The International Centre for Science in Drug Policy (ICSDP) today released a new research report that demonstrates the clear failure of U.S. marijuana prohibition and supports calls for evidence-based models to legalize and regulate the use of cannabis. The British Medical Journal, one of the world’s most influential medical journals, published a supportive commentary to coincide with the report’s release today.

Transform's submission to the Drugs Strategy Consultation

The summary and conclusions are copied below, the full document (in Pdf format) is available here. 

Transform has a number of serious concerns about the consultation process and the contents of the consultation paper itself. These concerns are explored first with reference to the consultation document where relevant, and the Governments consultation code of practice. We then highlight and discuss key areas of policy that are absent from the consultation. 
On the specific questions in the consultation document not covered in this response Transform wishes to endorse the detailed submissions made by Release ( www.release.org ) and UKHRA / NNEF. (www.ukhra.org ) 
Summary: 
The consultation does not adhere to the first three criterion of the Government’s consultation code of practice regarding when to consult, duration of the consultation, or clarity and scope of impact.
There is no Impact Assessment for proposed policy changes, or research data / analysis presented in support of any proposals.
Key areas of the public policy debate are entirely absent from the consultation, specifically: Harm reduction – a key pillar of UK drug policy receives no mention 
Sentencing / decriminalisation – the growing body of evidence, high level backing and active public debate are ignored
 Supply side enforcement – its efficacy is unquestioned (despite the absence of evidence) and its impacts unexplored
The classification system / ACMD – none of the high profile public debates and controversies on this important issue are addressed
International drug policy – there is no mention of or engagement with the international dimension of UK drug policy
Evaluative framework – there is no engagement with how policy should be evaluated – regards targets, KPIs and or how they should be prioritised
Tobacco – there are many mentions of alcohol, but none of the drug associated with the greatest number of addictions and chronic deaths in the UK  
Discussion / Conclusions 
There are some positive things in this consultation. We are pleased to see the call for ‘a more holistic approach with drugs issues being assessed and tackled alongside other issues such as alcohol abuse, child protection, mental health, employment and housing’.
Transform have long argued that levels of problematic drug use primarily reflect a complex interplay social, economic and cultural variables. In addition to those above we would certainly include social deprivation, inequality and broader measures of personal and social wellbeing. The corollary of this, of course, is that the impact of drug policy as traditionally conceived (prevention, treatment, and enforcement) should not be overestimated and may be marginal, in many cases irrelevant, relative to the underlying social determinants of drug using behaviours.
This analysis – that problematic use is essentially a barometer of a social wellbeing (or lack of) - has obvious implications for longer term prevention and harm reduction strategies. It suggests that success is likely to flow more from investment in social capital and addressing multiple deprivation and inequality issues, particularly as they affect young people, rather than from pouring ever more money into more conventional interventions that are poorly supported by evidence. 
Whilst conventional drug policy may only be able to achieve, at best, fairly marginal impacts on prevalence of problematic use, the overarching prohibitionist legal framework can, however, have a dramatic impact on levels of harm associated with drug use. This can be both by increasing health risks associated with use, and through the wider social harms created or exacerbated by the illegal drug market. 
This goes to the heart of the drug policy and law reform position that Transform represents; a pragmatic position that accepts both the reality of demand for drugs as it currently exists, and that this demand will be met by illegal supply routes if no legally regulated supply option exists. Drug markets can be controlled and regulated by governments or by gangsters; there is no third option that involves a drug free society. 
We argue that legally regulating drug production, supply and use (as detailed in ‘After the War on Drugs; Blueprint for Regulation’) would deliver better outcomes than the anarchic criminal free for all and underground drug culture we currently have. The pragmatic mindset also requires that whilst we acknowledge  most people do not use illegal drugs, we must also acknowledge that most of those who do, do so relatively responsibly. Their use is not associated with significant personal or social harms, and as such should not be deemed problematic. Of people (globally) who report using illegal drugs in the last year The UNODC only describes 5% as problematic users. It is important to be mindful of the 95% of non-problematic users who do not need treatment – let alone criminal sanction.

Whilst there is a welcome and growing acknowledgement that treatment, prevention and education should be are tailored to individual and local needs - prohibition remains a blunt, inflexible and indiscriminate legislative tool, an absolutist position that criminalises all users regardless of their impact on themselves or those around them, similarly forcing all supply in the hands of criminal profiteers.

The reform position has its roots in the critique of the failings of this approach – both on its own terms, and regards the secondary unintended harms of the illegal trade it fuels. As has been alluded to in this response, the prohibitionist paradigm cannot stand scrutiny, which is at least part of the reason why scrutiny has been so studiously avoided for so long. Indeed the ‘war on drugs’ has required a monumental propaganda effort to sustain it – just as many other wars have.
We only need cast our minds back to the farcical drug strategy consultation of 2007. It was supported by a consultation document described by the ACMD thus: "it is unfortunate that the consultation paper’s ‘key facts and evidence’ section appears to focus on trying to convince the reader of success and progress; rather than providing an objective review and presentation of the current evidence. The ACMD found the consultation paper self-congratulatory and generally disappointing.’
‘It is of concern that the evidence presented, and the interpretation given, are not based on rigorous scrutiny.'Of the same document the Government’s own Statistics Commission similarly accused the Home Office of spinning the data to make it look more favourable and failing to ‘provide a balanced presentation of the relevant statistical and other evidence’.   Meanwhile a rigorous and critical ‘value for money’ study (referred to on page 10) that informed the Home Office’s internal review was not made publicly available – only emerging this year following an absurdly protracted 3-year FOI battle with Transform. 
Many the problems with that ill fated consultation (regards process, content and transparency) have unfortunately now been repeated, although this time around we do not even have crudely spun evidence to criticise – there is simply none.
  This is why the core of our call in this response is to return to the evidence; to have, if you will forgive the oft-misused political clichés, a ‘mature and rational debate’ about ‘what works’.

But this time with all options on the table.
  This requires open, honest and ongoing evaluation, and as a starting point; independently overseen Impact Assessments of all policies and legislation, new and old (including the MDA 1971). 
In terms of the general mindset, this will entail a move from misplaced moralising and outdated (but entrenched) drug war ideologies to pragmatic public health and social policy norms. If the Government follow the evidence it can only lead to better policies and the better outcomes we all seek. We are confident that if this happens it will only lead in one direction – and it will not be towards criminalisation and prohibition. 
Sadly this consultation falls short on almost every front – it is tokenistic, politicised, and entirely inadequate for the reasons outlined. It is more than a missed opportunity; it is entirely unacceptable as a basis for developing a new drug strategy. We therefore recommend that it be reviewed by the Cabinet Office (and will be requesting this from the Cabinet Minister) with a view to being re-launched. The new consultation process should address the identified shortcomings by adhering to the Government code of practice, including evidential support and Impact Assessments for all proposals, and covering all aspects of UK drug policy of concern to stakeholders.

Anti-Smoking poster from 1915

 
There's something charmingly blunt about this . It also contains a number of strangely prescient cues for tobacco policy (and some elements of illegal drug policy) over the following century.

67 US law professors back California's prop 19 tax and regulate cannabis measure

The following statement and list of signatories is copied from the Yeson19.com website :

To the Voters of California:

As law professors at many law schools who focus on various areas of legal scholarship, we write this open letter to encourage a wholesale rethinking of marijuana policy in this country, and to endorse the Tax and Control Cannabis 2010 initiative—Proposition 19—that will be voted on in November in California.

For decades, our country has pursued a wasteful and ineffective policy of marijuana prohibition. As with alcohol prohibition, this approach has failed to control marijuana, and left its trade in the hands of an unregulated and increasingly violent black market. At the same time, marijuana prohibition has clogged California’s courts alone with tens of thousands of non-violent marijuana offenders each year. Yet marijuana remains as available as ever, with teens reporting that it is easier for them to buy than alcohol across the country.

Proposition 19 would remove criminal penalties for private use and cultivation of small amounts of marijuana by adults and allow California localities to adopt—if they choose—measures to regulate commerce in marijuana. Passage of Proposition 19 would be an important next step toward adopting an approach more grounded in reason, for California and beyond.

Our communities would be better served if the criminal justice resources we currently spend to investigate, arrest, and prosecute people for marijuana offenses each year were redirected toward addressing unsolved violent crimes. In short, the present policy is causing more harm than good, and is eroding respect for the law.

Moreover, we are deeply troubled by the consistent and dramatic reports of disproportionate enforcement of marijuana laws against young people of color. Marijuana laws were forged in racism, and have been demonstrated to be inconsistently and unfairly applied since their inception. These are independent reasons for their repeal.

Especially in the current economic climate, we must evaluate the efficacy of expensive government programs and make responsible decisions about the use of state resources. We find the present policies toward marijuana to be bankrupt, and urge their rethinking.

This country has an example of a path from prohibition. Alcohol is subject to a regulatory framework that is far safer in every respect than the days of Al Capone. Just like the State of New York did when it rolled back Prohibition 10 years before the nation as a whole, California should show leadership and restore respect for the law by enacting the Tax and Control Cannabis 2010 initiative this November.

Click here to sign and endorse!
Sincerely,

Jonathan H. Adler
Case Western Reserve University School of Law, Cleveland, Ohio

Ty Alper
University of California, Berkeley, School of Law, Berkeley, CA

Hadar Aviram
University of California, Hastings College of the Law, San Francisco, CA

W. David Ball
Santa Clara Law, Santa Clara, CA

Randy Barnett
Georgetown University Law Center, Washington, DC

Tom W. Bell
Chapman Law School, Orange, CA

Steve Berenson
Thomas Jefferson School of Law, San Diego, CA

Eric Berger
University of Nebraska, College of Law, Lincoln, NE

Douglas A. Berman
Moritz College of Law, Ohio State University, Columbus, OH

David E. Bernstein
George Mason University School of Law, Arlington, VA

Ash Bhagwat
University of California, Hastings College of the Law, San Francisco, CA

Richard Boldt
University of Maryland School of Law, Baltimore, MD

Sande Buhai
Loyola University School of Law, Los Angeles, CA

Paul Butler
George Washington University Law School, Washington, DC

Erwin Chemerinsky
University of California, Irvine, CA

Gabriel J. Chin
University of Arizona James E. Rogers College of Law, Tucson, AZ

Marjorie Cohn
Thomas Jefferson School of Law, San Diego, CA

Mary Culbert
Loyola University School of Law, Los Angeles, CA

Angela J. Davis
Washington College of Law, American University, Washington, DC

Alan M. Dershowitz
Harvard Law School, Cambridge, MA

Steven Duke
Yale Law School, New Haven, CT

Elizabeth Price Foley
Florida International University College of Law, Miami, FL

David Friedman
Santa Clara Law, Santa Clara, CA

Mary Ellen Gale
Whittier Law School, Costa Mesa, CA

Pratheepan Gulasekaram
Santa Clara Law, Santa Clara, CA

Bill Ong Hing
University of San Francisco School of Law, San Francisco, CA

Paige Kaneb
Santa Clara Law, Santa Clara, CA

Madeline June Kass
Thomas Jefferson School of Law, San Diego, CA

Alice Kaswan
University of San Francisco School of Law, San Francisco, CA

Alex Kreit
Thomas Jefferson School of Law, San Diego, CA

Ellen Kreitzberg
Santa Clara Law, Santa Clara, CA

David Levine
University of California, Hastings College of the Law, San Francisco, CA

Jerry Lopez
UCLA School of Law, Los Angeles, CA

Elizabeth Loftus
University of California, Irvine, CA

Erik Luna
Washington and Lee University School of Law, Lexington, VA

Michael Madow
Brooklyn Law School, Brooklyn, NY

Leigh Maddox
University of Maryland, School of Law, Baltimore, MD

Charles Marvin
Georgia State University College of Law, Atlanta, GA

Lawrence C. Marshall
Stanford Law School, Stanford, CA

David N. Mayer
Capital University Law School, Columbus, OH

Tracy L. McGaugh
Touro Law Center, Central Islip, NY

Andrew P. Morriss
University of Alabama, School of Law, Tuscaloosa, AL

Michelle Oberman
Santa Clara Law, Santa Clara, CA

Tamara R. Piety
University of Tulsa College of Law, Tulsa, OK

Ascanio Piomelli
University of California, Hastings College of the Law, San Francisco, CA

David G. Post
Beasley School of Law, Temple University, Philadelphia, PA

Jenny Roberts
Washington College of Law, American University, Washington, DC

Cesare Romano
Loyola University School of Law, Los Angeles, CA

Margaret Russell
Santa Clara Law, Santa Clara, CA

Barry C. Scheck
Benjamin N. Cardozo School of Law, New York, NY

Steven Semeraro
Thomas Jefferson School of Law, San Diego, CA

Steven Shatz
University of San Francisco School of Law, San Francisco, CA

Jonathan Simon
University of California, Berkeley, School of Law, Berkeley, CA

Eric S. Sirulnik
George Washington University Law School, Washington, DC

David Sloss
Santa Clara Law, Santa Clara, CA

Abbe Smith
Georgetown University Law Center, Washington, DC

Ilya Somin
George Mason University School of Law, Arlington, VA

Clyde Spillenger
UCLA School of Law, Los Angeles, CA

Edward Steinman
Santa Clara Law, Santa Clara, CA

Mark Strasser
Capital University Law School, Columbus, OH

Robert N. Strassfeld
Case Western Reserve University School of Law, Cleveland, Ohio

Nadine Strossen
New York Law School, New York, NY

Gerald F. Uelmen
Santa Clara Law, Santa Clara, CA

Alexander Volokh
Emory Law School, Atlanta, GA

Keith Wingate
University of California, Hastings College of the Law, San Francisco, CA

Eric Wright
Santa Clara Law, Santa Clara, CA

Richard W. Wright
Illinois Institute of Technology
Kent College of Law, Chicago, IL

Transform launches updated and re-designed 'Comparative Cost-Effectiveness of Drug Prohibition/Regulation' report

On the eve of the Comprehensive Spending Review it seems like an opportune moment to relaunch Transform's 2009 report: 'A Comparison of the Cost-Effectiveness of Prohibition and regulation of Drugs', now updated and beautifully redesigned (available online pdf). The publication created a decent media splash, led to a PQ and ultimately a meeting with the Prime Minister (see below for summary and details). 

UN expert calls for a fundamental shift in global drug control policy

Media Advisory
At a press conference in New York on Tuesday 26 October, at the 65th session of the United Nations General Assembly, one of the UN’s key human rights experts will call for a fundamental rethink of international drug policy.
Anand Grover, from India, is the UN Special Rapporteur on the Right of Everyone to the Highest Attainable Standard of Physical and Mental Health, whose mandate is derived from the UN Human Rights Council. Mr Grover’s annual thematic report, to be presented on October 25/26, sets out the range of human rights abuses that have resulted from international drug control efforts, and calls on Governments to:
Ensure that all harm-reduction measures (as itemized by UNAIDS) and drug-dependence treatment services, particularly opioid substitution therapy, are available to people who use drugs, in particular those among incarcerated populations. Decriminalize or de-penalize possession and use of drugs.Repeal or substantially reform laws and policies inhibiting the delivery of essential health services to drug users, and review law enforcement initiatives around drug control to ensure compliance with human rights obligations.Amend laws, regulations and policies to increase access to controlled essential medicinesTo the UN drug control agencies, Mr Grover recommends the creation of an alternative drug regulatory framework based on a model such as the Framework Convention on Tobacco Control.

The report is the clearest statement to date from within the UN system about the harms that drug policies have caused and the need for a fundamental shift in drug policy.
The report has been welcomed by the European Union in the EU statement on crime and drugs to the UN General Assembly.
Press conference details: Tuesday, 26 October at 1:15pm at the Dag Hammarskjöld Auditorium, New York, (close to the UN library in the Secretariat Building - entrance on 42nd Street and 1st Avenue). There will be a press release issued.
Mr Grover WILL NOT BE AVAILABLE for press comment prior to the press conference.
For press enquiries please contact:
Fiona Lander, MBBS(Hons)/LLB(Hons)
Research Assistant to Anand Grover, UN Special Rapporteur on the Right to Health

High Society: Wellcome Collection exhibition of drugs in history

A new, free exhibition (curated by Transform trustee and author Mike Jay) is opening tomorrow at the Wellcome Collection in London and will be running until February the 27th 2011. The exhibition will explore the role of mind-altering drugs in our history.